Biogen (BIIB) PT Raised to $300 at Wedbush, After FDA Approves Aduhelm (Aducanumab)
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $210.65 --0%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 3
Join SI Premium – FREE
Wedbush analyst Laura Chico raised the price target on Biogen (NASDAQ: BIIB) to $300.00 (from $240.00) while maintaining a Neutral rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- InterContinental Hotels Group (IHG:LN) (IHG) PT Lowered to $178 at Barclays
- Powszechna Kasa Oszczednosci Bank Polski SA (PKO:WA) (PSZKF) PT Raised to PLN101 at Barclays
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
